Indices dipped after Johnson & Johnson (JNJ.US) release results of coronavirus vaccine trials. The company said that its one-shot vaccine is 66% effective overall in moderate to severe cases, according to findings of the global clinical trial. Shots were generally well tolerated among trial participants. This is a slightly disappointing result given that some available vaccines have prevented virus infections in over 90% of cases. However, the vaccine is said to be 85% effective in preventing severe cases. Company plans to file for the emergency use approval in the United States in early February.
DE30 dropped around 1% following lacklustre results of Johnson&Johnson coronavirus vaccine trials. Source: xStation5
Daily Summary: End of the week in the red, tech rally waning
Three Markets to Watch Next Week (12.12.2025)
Technology companies declines ๐๐ฅ๏ธ
US OPEN: Valuations under pressure amid deregulation spree